All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What is the clinical significance of secondary-AML-type mutations in de novo AML?

Aug 6, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in AML

During the EHA 2022 Congress, the AML Hub spoke with Isolda Fernandez, FUNDALEU, Buenos Aires, AR. We asked, What is the clinical significance of secondary-AML-type mutations in de novo AML?

What is the clinical significance of secondary-AML-type mutations in de novo AML

Fernandez discusses the importance of the identification of AML mutations and the prognostic effects on patients (e.g., NPM1 and TP53 mutations). Fernandez outlines the incidence of mutations, and discusses a presentation from the EHA 2022 Congress about clinical and prognostic implications of secondary-AML-type mutations in de novo patients with AML.